Future Perspectives for the Development of Chemotherapy for Advanced Gastric Cancer: Japanese and Global Status

被引：2
作者：
Higuchi, Katsuhiko [1 ]
Tanabe, Satoshi [1 ]
Azuma, Mizutomo [1 ]
Sasaki, Tohru [1 ]
Ishido, Kenji [1 ]
Koizumi, Wasaburo [1 ]
机构：
[1] Kitasato Univ, Sch Med, Dept Gastroenterol, Minami Ku, Sagamihara, Kanagawa 2520380, Japan
来源：
PATHOBIOLOGY | 2011年 / 78卷 / 06期
关键词：
Gastric cancer; Chemotherapy; Molecular target agent; Personalized therapy; PHASE-III TRIAL; ADVANCED ESOPHAGOGASTRIC CANCER; S-1 PLUS CISPLATIN; 1ST-LINE TREATMENT; FLUOROURACIL; DOXORUBICIN; METHOTREXATE; CAPECITABINE; OXALIPLATIN; MITOMYCIN;
D O I：
10.1159/000321700
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
In Japan, gastric cancer is the second leading cause of cancer-related mortality after lung cancer. Many randomized trials of various chemotherapeutic regimens have been conducted, contributing to improved outcomes in patients with advanced gastric cancer (AGC). The standard regimen for AGC is a combination of S-1 and cisplatin in Japan. Recently, new drug development has focused on molecular target agents, and personalized therapy for AGC has just begun. In patients with human epidermal growth factor receptor 2-positive AGC, trastuzumab in combination with chemotherapy improves survival. Furthermore, abundant information about the heterogeneity and biological backgrounds of AGC patients has been compiled. New strategies for the development of personalized therapy should be studied in the future. Copyright (C) 2011 S. Karger AG, Basel
引用
收藏
页码：334 / 342
页数：9
相关论文
共 50 条
  • [31] Advanced gastric cancer: Current treatment landscape and future perspectives
    Digklia, Antonia
    Wagner, Anna Dorothea
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (08) : 2403 - 2414
  • [32] A phase II study of doxifluridine and docetaxel combination chemotherapy for advanced or recurrent gastric cancer
    Yoshikawa, Takaki
    Tsuburaya, Akira
    Shimada, Ken
    Sato, Atsushi
    Takahashi, Makoto
    Koizumi, Wasaburo
    Yoshizawa, Yasuo
    Nabeshima, Kazuhito
    Kimura, Masayuki
    Hataya, Kiyoshi
    Kobayashi, Osamu
    GASTRIC CANCER, 2009, 12 (04) : 212 - 218
  • [33] Recent developments in chemotherapy of advanced gastric cancer
    Götze, T
    Schütte, K
    Röcken, C
    Malfertheiner, P
    Ebert, MPA
    DIGESTIVE DISEASES, 2004, 22 (04) : 360 - 365
  • [34] Chemotherapy for advanced gastric cancer
    Webb, A
    Cunningham, D
    GI CANCER, 1997, 2 (02): : 143 - 148
  • [35] Current status and future prospects of chemotherapy for metastatic gastric cancer: A review
    Ohtsu A.
    Gastric Cancer, 2005, 8 (2) : 95 - 102
  • [36] Current status of adjuvant chemotherapy for gastric cancer
    Kim, In-Hwan
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 11 (09) : 679 - 685
  • [37] S-1 Combined with Oxaliplatin as First Line Chemotherapy for Chinese Advanced Gastric Cancer Patients
    Liu, Bixia
    Ying, Jieer
    Luo, Cong
    Xu, Qi
    Zhu, Liming
    Zhong, Haijun
    HEPATO-GASTROENTEROLOGY, 2012, 59 (114) : 649 - 653
  • [38] Induction chemotherapy for oral cavity cancer patients: Current status and future perspectives
    Marta, Gustavo Nader
    William, William N., Jr.
    Feher, Olavo
    Carvalho, Andre Lopes
    Kowalski, Luiz Paulo
    ORAL ONCOLOGY, 2015, 51 (12) : 1069 - 1075
  • [39] Chemotherapy Options for Locally Advanced Gastric Cancer: A Review
    Semenova, Yuliya
    Kerimkulov, Altay
    Uskenbayev, Talgat
    Zharlyganova, Dinara
    Shatkovskaya, Oxana
    Sarina, Tomiris
    Manatova, Almira
    Yessenbayeva, Gulfairus
    Adylkhanov, Tasbolat
    CANCERS, 2025, 17 (05)
  • [40] A Case of Advanced Gastric Cancer with Folfiri as a Preoperative Chemotherapy
    Hieu Van Nguyen
    Hung Van Nguyen
    Long Thanh Nguyen
    Nga Quynh Pham
    Hau Xuan Nguyen
    Hien Xuan Nguyen
    Vuong Thi Nguyen
    CASE REPORTS IN ONCOLOGICAL MEDICINE, 2019, 2019
12345